LPCN Lipocine Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1535955 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-13.4%
TTM net income YoY-70.4%
TTM EPS YoY-22.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-269.1%
Net margin-249.2%
FCF margin—
EBITDA margin-267.5%
Returns
ROE-52.9%
ROA-47.5%
ROIC (approx.)-55.3%
Asset turnover0.19x
Leverage & solvency
Liabilities / assets8.8%
Debt / equity0.00x
Current ratio11.36x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.07x
Accruals ratio3.5%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $2.29M | $190,099 | $119,397 | $1.15M | $114,574 | $622,849 | $93,864 | $3.49M |
| R&D expense | $2.07M | $2.04M | $2.76M | $2.68M | $2.71M | $2.14M | $1.06M | $1.07M |
| SG&A expense | $1.09M | $990,956 | $1.20M | $983,390 | $767,837 | $890,433 | $1.12M | $873,055 |
| Operating income | -$868,525 | -$2.84M | -$3.85M | -$2.52M | -$3.36M | -$2.40M | -$2.09M | $1.55M |
| Pretax income | -$666,192 | -$2.62M | -$3.67M | -$2.37M | -$3.19M | -$2.21M | -$1.86M | $1.78M |
| Income tax | $0 | $200 | — | $0 | $0 | $0 | $200 | $0 |
| Net income | -$666,192 | -$2.62M | -$3.67M | -$2.37M | -$3.19M | -$2.21M | -$1.86M | $1.78M |
| EBITDA | -$853,878 | -$2.83M | -$3.83M | -$2.50M | -$3.35M | -$2.39M | -$2.07M | $1.56M |
| EPS (basic) | -0.08 | -0.32 | -0.54 | — | -0.59 | -0.41 | -0.35 | — |
| EPS (diluted) | -0.08 | -0.32 | -0.54 | — | -0.59 | -0.41 | -0.35 | — |
| Weighted avg. shares (diluted) | 8.24M | 8.22M | 6.80M | — | 5.41M | 5.35M | 5.35M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $2.59M | $4.98M | $5.02M | $5.21M | $3.90M | $6.04M | $3.35M | $6.21M |
| Short-term investments | $18.86M | $18.29M | $19.71M | $9.72M | $11.23M | $11.89M | $16.36M | $15.43M |
| Current assets | $23.11M | $23.74M | $25.24M | $16.88M | $15.93M | $18.42M | $20.33M | $22.32M |
| PP&E, net | $60,184 | $74,831 | $89,479 | $104,293 | $119,274 | $133,397 | $149,505 | $165,075 |
| Total assets | $23.20M | $23.84M | $25.36M | $17.01M | $16.07M | $18.58M | $20.50M | $22.51M |
| Current liabilities | $2.03M | $2.07M | $2.53M | $2.53M | $1.93M | $1.45M | $1.30M | $1.51M |
| Total liabilities | $2.03M | $2.07M | $2.53M | $2.53M | $1.93M | $1.45M | $1.30M | $1.51M |
| Shareholders' equity | $21.16M | $21.77M | $22.83M | $14.48M | $14.14M | $17.13M | $19.20M | $21.00M |
| Shares outstanding | 8.25M | 8.24M | 7.48M | 6.16M | 5.42M | 5.37M | 5.35M | 5.35M |
| Cash flow statement | ||||||||
| Operating cash flow | -$1.81M | -$3.03M | -$2.26M | -$2.92M | -$2.99M | -$1.89M | -$1.97M | $1.70M |
| Capital expenditure | — | — | — | — | — | — | — | $10,019 |
| Free cash flow | — | — | — | — | — | — | — | $1.69M |
| Investing cash flow | -$577,630 | $1.48M | -$9.90M | $1.57M | $701,449 | $4.50M | -$882,073 | $761,058 |
| Financing cash flow | $0 | $1.51M | $11.97M | $2.65M | $141,334 | — | — | $0 |
| Depreciation & amortization | $14,647 | $14,648 | $14,814 | $14,981 | $14,123 | $16,108 | $15,570 | $15,571 |
| Stock-based compensation | $74,094 | $58,145 | $65,398 | $53,034 | $53,256 | $65,205 | $71,002 | $99,086 |
Free plan shows the latest 8 periods; Pro shows all 61 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.